NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
Rhea-AI Summary
Vanda Pharmaceuticals (Nasdaq: VNDA) announced that its NEREUS™ branded No. 47 IndyCar, fielded by Rahal Letterman Lanigan Racing and driven by Mick Schumacher, will compete in the inaugural Freedom 250 Grand Prix of Washington, D.C., held August 22–23, 2026 on the National Mall.
NEREUS™ (tradipitant), described by Vanda as the first new U.S. prescription medication in 47 years approved to prevent motion-induced vomiting, is the primary sponsor of the No. 47 Honda. The race weekend serves as a home event for the Washington-based company and will be broadcast live on FOX.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 05 | Q2 earnings report | Neutral | +0.5% | Mixed quarterly sales and loss results accompanied by a small positive reaction. |
| Jul 29 | Earnings date notice | Neutral | +2.6% | Scheduled Q2 results release and conference call announcement preceded positive reaction. |
| Jul 16 | Regulatory designation | Positive | -0.2% | EMA positive opinion recommended orphan designation for imsidolimab in generalized pustular psoriasis. |
| Jul 15 | NEREUS sponsorship | Positive | -6.8% | NEREUS sponsorship of No. 47 IndyCar entry preceded substantial negative reaction. |
| Jul 10 | Summit participation | Neutral | -3.9% | Scheduled participation in B. Riley summit preceded a negative reaction. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent reactions were mixed, including a -6.84% move after the prior NEREUS sponsorship announcement and +0.49% after Q2 results.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The event, taking place August 22–23, 2026, celebrates America's 250th anniversary with high-speed racing on a 1.7-mile, seven-turn temporary street circuit framed by the Washington Monument,
NEREUS™ (tradipitant), the first new
"Partnering with the No. 47 car perfectly captures this historic moment and our shared commitment to performance under challenging conditions," said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda.
Fans can follow the No. 47 NEREUS™ IndyCar as Schumacher and Rahal Letterman Lanigan Racing take on this landmark street circuit in the nation's capital.
About NEREUS™ (tradipitant)
NEREUS™ is an oral NK-1 receptor antagonist FDA-approved for the prevention of vomiting induced by motion in adults. It is the first new pharmacologic treatment approved for this indication in over four decades.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com and follow us on X @vandapharma.
About Rahal Letterman Lanigan Racing
Rahal Letterman Lanigan Racing is a championship-winning team competing in the NTT IndyCar Series.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nereus-sponsored-no-47-indycar-ready-for-historic-freedom-250-grand-prix-in-washington-dc-302857737.html
SOURCE Vanda Pharmaceuticals Inc.